We investigated the PI3K/AKT pathway because it is strictly associated with CLL pathogenesis49, and PI3Kδ, one of the main activators of AKT in CLL cells50, is a therapeutic target in this leukemia51,52. Here, AKT1 is linked to B-cell chronic lymphocytic leukemia.